Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Licensing Agreement Renewal with Nuka Enterprises Reinforces DehydraTECH™ Revenue Strategy
Report: LXRP is a ‘compelling investment opportunity’ which is creating recurring licensing revenue that unlocks shareholder value LXRP’s DehydraTECH is a patented delivery technology platform that is renewal-licensed by Nuka in a 10-year semi-exclusive agreement that expands its reach into Canada Company is growing its patent portfolio for proprietary DehydraTECH; it already has patents granted in Australia and the U.S. and has patents pending in more than 40 countries worldwide Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) renewal of its DehydraTECH™ license with Nuka Enterprises LLC could help make it a compelling investment opportunity in the cannabis industry as its…